Skip to content

Study on the Optimal Waveform Patterns of Electroacupuncture Targeted Intervention for Bell's Palsy Based on Surface Electromyography Characteristics

Study on the Optimal Waveform Patterns of Electroacupuncture Targeted Intervention for Bell's Palsy Based on Surface Electromyography Characteristics

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07598175
Enrollment
100
Registered
2026-05-20
Start date
2026-09-01
Completion date
2028-11-20
Last updated
2026-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bell's Palsy

Brief summary

The goal of this clinical study is to find out whether different electronic acupuncture wave forms can effectively treat recovery-stage Bell's palsy in adults and evaluate their safety. The main questions it aims to answer are: * Can targeted electronic acupuncture wave forms improve facial nerve function in patients with Bell's palsy? * What is the optimal electronic acupuncture waveform for different degrees of facial nerve injury? * What adverse events may occur during electronic acupuncture treatment? Researchers will compare low-frequency continuous wave electronic acupuncture and intermittent wave electronic acupuncture to determine which waveform works better for recovery-stage Bell's palsy. Participants will: * Receive either low-frequency continuous wave electronic acupuncture or intermittent wave electronic acupuncture every other day for 4 weeks * Undergo surface sEMG and ENoG examinations at baseline, Week 2, and Week 4 * Complete facial function assessments and safety evaluations at each clinic visit

Interventions

PROCEDUREelectroacupuncture waveform

The non-severe injury group was randomly divided into two subgroups: one treated with low-frequency continuous wave and the other with intermittent wave.The severe injury group was also randomly divided into two subgroups: one treated with low-frequency continuous wave and the other with intermittent wave.

Sponsors

The Third Affiliated hospital of Zhejiang Chinese Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

for Bell's Palsy Subjects: * Meet the above Bell's palsy diagnostic criteria; * Age 18-65 years, either gender; * Disease course in recovery phase (21 days ≤ course ≤ 6 months) and not recovered (FNGS 2.0 score \>4); * Voluntarily participate in this study and sign informed consent. Inclusion Criteria for Healthy Subjects: * Do not meet the above Bell's palsy diagnostic criteria; * Age 18-65 years, either gender, matched to Bell's palsy subjects within 5 years for age and gender; * Normal facial nerve function, FNGS 2.0 score = 4; * Voluntarily participate in this study and sign informed consent.

Exclusion criteria

for Bell's Palsy Subjects: * Facial trauma, skin lesions, or other diseases that may cause facial paralysis symptoms; * Diagnosed with Ramsay Hunt syndrome (herpes zoster oticus); * Bilateral facial paralysis; * Previous history of facial paralysis; * Facial synkinesis, contracture, or spasm already present; * History of facial surgery; * Uncontrolled diabetes, hypertension, severe cardiac, hepatic, or renal disease, cognitive impairment, aphasia, or mental disorders; * Pacemaker use; * Pregnant or lactating patients.

Design outcomes

Primary

MeasureTime frameDescription
FNGS2.0week4FNGS 2.0 stands for Facial Nerve Grading System 2.0, with a total score range of 4 to 24; lower scores indicate better facial nerve function (4 = normal), while higher scores indicate more severe facial paralysis (24 = complete facial palsy).

Secondary

MeasureTime frameDescription
Sunnybrook Facial Grading System,SBGSweek41.SBGS:Score range: 0-100, with higher scores indicating better facial nerve function.

Contacts

CONTACTJing Sun
sunjing0268@163.com13429610268

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 3, 2026